NeurAxis Announces Blue Cross And Blue Shield Of Kansas City Policy Coverage
Portfolio Pulse from Benzinga Newsdesk
NeurAxis, Inc. (NYSE:NRXS), a medical technology company, announced that Blue Cross and Blue Shield of Kansas City (BCBSKC) will now cover its neuromodulation therapies, expanding its coverage to approximately 9.25 million individuals. This development is part of NeurAxis's commercial strategy to leverage clinical evidence for its IB-Stim technology to obtain payer coverage and drive market adoption.

March 04, 2024 | 2:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeurAxis, Inc. announced expanded insurance coverage for its neuromodulation therapies by BCBSKC, significantly increasing its potential market reach.
The announcement of BCBSKC policy coverage for NeurAxis's therapies is a significant development for the company. It not only expands the potential customer base by approximately one million lives but also serves as a testament to the clinical evidence and potential market adoption of its IB-Stim technology. This could lead to increased revenues and further insurance partnerships, positively impacting the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90